Answer
The short answer
A prior authorization asks your plan to apply its own rule. A Part D formulary exception asks it to set the rule aside, needs your prescriber's supporting statement, and must be granted once the drug is found medically necessary.
A prior authorization is a request to be measured against a published rule. The drug is covered, the plan wants conditions documented, and the answer turns on whether your file meets them.
A formulary exception is a request to be let past the rule. On Medicare Part D it is used to get a drug that is not on the plan's formulary at all — or, and this is the part most people miss, to have a utilization management requirement waived on a drug that is on it.
That second use is the one to understand. The regulation defines formulary use to include cost utilization tools such as a dose restriction or a step therapy requirement or a therapeutic substitution. So on Part D, a step therapy requirement you cannot satisfy is not only a prior authorization problem. It is something an exception request can be pointed at.
This is the sharpest difference and it favors you. On a formulary exception the plan must grant it whenever it determines that the drug is medically necessary, consistent with the prescriber's statement, and that the drug would be covered but for being off-formulary. That is a duty, not a discretion.
A prior authorization carries no equivalent sentence. It is a determination against criteria, and if the criteria are not met the answer is no.
One boundary worth stating so you are not misled the other way: the prescriber's supporting statement is required, but supplying it does not decide anything by itself. The regulation says so directly — nothing in it should be read to mean the supporting statement will produce an automatic favorable decision.
For a formulary exception, that every covered Part D drug on any tier of the plan's formulary for the same condition either would not be as effective for you as the requested drug, or would have adverse effects for you, or both. Any tier — the comparison has to sweep the whole formulary, not just the preferred shelf.
The statement may be given orally first, and the plan may then require it in writing.
There is a second kind of exception that is easy to confuse with this one. A tiering exception is about price rather than coverage: it asks for a non-preferred drug at the cost-sharing of a preferred tier, and its supporting statement compares against the preferred drugs only. Different request, different standard, different outcome.
Not when you call. On an exception request the plan's 72-hour clock runs from receipt of the prescriber's supporting statement, and the expedited clock of 24 hours does the same. That is why chasing your prescriber's office matters more than chasing the plan.
There is a backstop, and the agency's own consumer page does not mention it. If the supporting statement has not arrived by the end of 14 calendar days from receipt of the exception request, the plan must decide anyway within 72 hours of that point — or 24 hours on the expedited track. We are flagging this because a reader who relies on the plain-language page alone will not know a decision is coming with or without the statement.
Then the silence is itself the denial, and it moves you along rather than stranding you. Where the plan fails to notify you within the applicable timeframe, that failure constitutes an adverse coverage determination, and the plan must forward your request to the independent review entity within 24 hours of the deadline expiring.
That is a better outcome than it sounds. It gets your case in front of a reviewer the plan does not control without you having to file anything further.
On Part D, in a defined window, yes. A plan must ensure access to a temporary supply within the first 90 days of coverage under a new plan, and provide a one-time temporary supply of at least an approved month's supply when you request a fill in that period.
It explicitly covers drugs that are on the formulary but blocked behind prior authorization or step therapy, not only drugs that are missing from it. Written notice has to follow within three business days of the temporary fill being processed.
The exception machinery above is Part D's. A commercial or employer plan uses the internal appeal route instead, on its own regulation and its own deadlines, and a Medicaid denial runs through the plan appeal and fair hearing route.
Getting this wrong wastes the thing you have least of. Asking a commercial plan for a formulary exception by name, or asking a Part D plan for an internal appeal by name, gets you a confused call rather than a filing.
What to say on the phone
I am requesting a formulary exception under my Part D plan for [drug name], and my prescriber will submit a supporting statement. Please confirm the fax number or portal for that statement and tell me the date the 72-hour clock starts. Please also give me the reference number for this coverage determination request.
Keep the reference number. Every later deadline on this route is measured from the decision on that request, and it is the one fact nobody writes down.
If something here decides anything for you, read the source rather than our summary of it. These are the documents we opened, and the month we opened them.
A formulary exception reaches utilization management, not just missing drugs. The regulation states that "Formulary use includes the application of cost utilization tools, such as a dose restriction, including the dosage form, that causes a particular Part D drug not to be covered for the number of doses prescribed or a step therapy requirement that causes a particular Part D drug not to be covered until the requirements of the plan's coverage policy are met, or a therapeutic substitution."
42 CFR §423.578(b), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
The plan has a duty to grant it once medical necessity is found. "The Part D plan sponsor must grant an exception whenever it determines that the drug is medically necessary, consistent with the physician's or other prescriber's statement under paragraph (b)(5) of this section, and that the drug would be covered but for the fact that it is an off-formulary drug." The same section also closes the opposite misreading: nothing in it "should be construed to mean that the physician's or other prescriber's supporting statement required for an exceptions request will result in an automatic favorable decision."
42 CFR §423.578(b) and (f), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
The supporting statement has to sweep the whole formulary. A prescriber "must provide an oral or written supporting statement that the requested prescription drug is medically necessary to treat the enrollee's disease or medical condition because— (i) All of the covered Part D drugs on any tier of a plan's formulary for treatment for the same condition would not be as effective for the enrollee as the non-formulary drug, would have adverse effects for the enrollee, or both." If the statement is given orally, "the Part D plan sponsor may require the physician or other prescriber to subsequently provide a written supporting statement."
42 CFR §423.578(b)(5) and (b)(6), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
The clock starts at the supporting statement, with a 14-day backstop. The plan must decide "as expeditiously as the enrollee's health condition requires, but no later than 72 hours after receipt of the request. For an exceptions request, the Part D plan sponsor must notify the enrollee... no later than 72 hours after receipt of the physician's or other prescriber's supporting statement. If a supporting statement is not received by the end of 14 calendar days from receipt of the exceptions request," the plan must decide "no later than 72 hours from the end of 14 calendar days from receipt of the exceptions request."
42 CFR §423.568(b), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
Missing the clock counts as a denial and moves your case on automatically. "If the Part D plan sponsor fails to notify the enrollee of its determination in the appropriate timeframe under paragraphs (b) or (c) of this section, the failure constitutes an adverse coverage determination, and the plan sponsor must forward the enrollee's request to the IRE within 24 hours of the expiration of the adjudication timeframe."
42 CFR §423.568(h), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
A Part D transition supply exists, and it covers drugs blocked by prior authorization. The plan must "Ensure access to a temporary supply of drugs within the first 90 days of coverage under a new plan," and provide "a one-time, temporary supply of at least an approved month's supply of medication" — a duty the rule applies to non-formulary drugs "including Part D drugs that are on a plan's formulary but require prior authorization or step therapy under a plan's utilization management rules." Written notice must reach you "within 3 business days after adjudication of the temporary fill."
42 CFR §423.120(b)(3), Electronic Code of Federal Regulations, effective August 2026 · source · read August 2026
The agency's plain-language version says the same thing in one sentence: "A formulary exception should be requested to obtain a Part D drug that is not included on a plan sponsor's formulary, or to request to have a utilization management requirement waived (e.g., step therapy, prior authorization, quantity limit) for a formulary drug." ⚠ Read it alongside the regulation rather than instead of it: this page gives the 24-hour and 72-hour clocks but does not mention the 14-calendar-day backstop above, and it prints a last-modified date of September 2024.
Centers for Medicare & Medicaid Services, Part D exceptions, effective September 2024 · source · read August 2026
None of this reaches a weight-loss prescription on its own, and the reason is definitional rather than clinical. Part D's own statute excludes the categories a state may exclude from Medicaid, and the first of those is "Agents when used for anorexia, weight loss, or weight gain." A drug outside the definition of a covered Part D drug is not something an exception can attach to — which is why the route for a GLP-1 on Medicare runs through an approved indication that is not weight loss.
42 U.S.C. §1396r-8(d)(2)(A), incorporated by §1395w-102(e)(2), Legal Information Institute · source · read August 2026
American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what published rules say. Your own plan documents and your own notice govern your case, and rules change — check the sources before you act.